



In tro duc tion: We hypot he si zed that pa tien ts wi th stab le an gi na ha ve in crea sed plas ma le ve ls of mR NA from ge nes res pon sib le for at he ros cle ro tic 
plaque de ve lop me nt and des ta bi li sa tion, i.e. from dea th-as so cia ted pro tein ki na se (DAP K1) and mo no cyte che mo tac tic pro tei n-1 (CCL2).
Ma te ria ls and met ho ds: Nuc leic aci ds we re iso la ted from plas ma of pa tien ts wi th sta bi le an gi na and heal thy sub jec ts as con tro ls. mR NAs we re 
tran scri bed to cDNAs, quan ti fi ed by rea l-ti me PCR and stan dar di zed to the amou nt of a re fe ren ce ge ne. Rea gen ts for PCR quan ti fi  ca tion are dec la red 
to be mR NA spe ci fi c, but in our te st con di tio ns DNA was fou nd to in ter fe re in bo th as says.
Re sul ts: Pa tien ts had 5.1-times hig her plas ma le vel of DAP K1 nuc leic aci ds (mR NA and DNA) than con tro ls (P < 0.001) and the hig he st le ve ls we re 
as so cia ted wi th the pre sen ce of dia be tes. Howe ver, plas ma le ve ls of CCL2 ten ded to be lower than in con tro ls, and in sta ti n-trea ted pa tien ts the dec-
re me nt reac hed sig ni fi  cance (-66.3%; P = 0.041).
Con clu sion: The es ti ma ted le ve ls are expli cab le in ter ms of cur re nt knowled ge. Fur ther stu dies wi th spe ci fi c as says for mR NA PCR quan ti fi  ca tion 
are rea so nab le to ac ce ss whet her this ap proa ch off e rs no n-in va si ve in vi vo as ses sme nt and mo ni to ri ng of ge ne expres sion pro fi  le in at he ros cle ro tic 
vas cu lar be ds.
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Original articles
In tro duc tion
Dea th-as so cia ted pro tein ki na se (en co ded by DAP-
K1) is a proa pop to tic, cal mo du li n-re gu la ted se ri ne/
threonine ki na se that car ries a C-ter mi nal dea th 
do main. Apop to sis has been iden ti fi ed as a pro mi-
ne nt fea tu re of at he ros cle ro sis (1) and DAP K1 mR-
NA and DAP K1 are in crea sed in ca ro tid at he ros cle-
ro tic plaques (2). Mo no cyte che mo tac tic pro tei n-1 
(en co ded by CCL2) is in vol ved in the for ma tion, 
prog res sion, and des ta bi li za tion of at he ros cle ro tic 
plaques (3). A fol low-up stu dy in hyper cho les te ro-
le mic rab bi ts showed that the in crea se of CCL2 
mR NA in ar te rial wa ll cor re la ted wi th at he ros cle ro-
tic plaque de ve lop me nt (4).
Ce ll-free nuc leic aci ds are nuc leic aci ds (DNA, mR-
NA) pre se nt in plas ma, se rum and ce ll-free frac tio-
ns of va rious ot hers bio lo gi cal fl ui ds (5). As to co ro-
na ry ar te ry di sea se, the prog nos tic va lue of nuc leic 
aci ds in the plas ma of pa tien ts wi th acu te co ro na-
ry syndro me has been es tab lis hed (6,7) and pa-
tien ts wi th co ro na ry at he ros cle ro sis ha ve in crea-
sed plas ma cat hep sin S mR NA le ve ls (8). We pro-
po sed that it shou ld be pos sib le to mea su re DAP K1 
mR NA and CCL2 mR NA le ve ls, i.e. from ge nes res-
pon sib le for plaque de ve lop me nt and des ta bi li za-
tion, in plas ma of pa tien ts wi th co ro na ry at he ros-
cle ro sis, and we hypot he si zed that the se le ve ls are 
in crea sed. If the an swe rs we re po si ti ve, it wou ld 
mean that plas ma mR NA es ti ma tion cou ld off er 
no n-in va si ve in vi vo as ses sme nt and mo ni to ri ng of 
ge ne expres sion pro fi  le in at he ros cle ro tic vas cu lar 
be ds.
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Ma te ria ls and met ho ds
Pa tien ts
Ma te ria ls and met ho ds (8) and op ti mi sa tion of pro-
to co ls (9,10) we re in de tail des cri bed pre vious ly. 
Briefl y, pa tien ts we re con se cu ti ve ly en rol led from 
tho se wi th stab le an gi na or acu te co ro na ry syndro-
me un der goi ng rou ti ne co ro na ry an giog rap hy. 
Stab le an gi na and acu te co ro na ry syndro me we re 
diag no sed by cli ni cal as ses sme nt, EKG eva lua tion 
and la bo ra to ry fi n din gs. In fl am ma to ry, thyroid, li-
ver, en doc ri ne, neop las tic and re nal disea ses (se-
rum crea ti ni ne con cen tra tion va lues ≥ 120 μmol/L) 
we re exclu ded by de tai led his to ry and cli ni cal exa-
mi na tion. The stu dy was ap pro ved by the na tio nal 
et hi cs com mit tee. In for med con se nt was ob tai ned 
from all par ti ci pa ti ng sub jec ts.
Met ho ds
Pe rip he ral blood was ta ken into EDTA tu bes (Bec-
ton Dic kin son, Plymou th, UK) af ter at lea st 12 hou-
rs of fas ti ng and be fo re co ro na ry an giog rap hy. To 
re du ce the bias re sul ti ng from in sta bi li ty of mR NA 
the sa me doub le-spin pro ce du re was used in all 
sub jec ts to ob tain plas ma nuc leic aci ds. Sam ple 
pro ces si ng took pla ce wit hin one hour of col lec-
tion. Hae mo lysed sam ples we re not used for ana-
lysis.
RNA was iso la ted from plas ma usi ng QIAa mp Mi-
nE lu te Vi rus Spin Kit (Qia gen, Hil den, Ger ma ny) ac-
cor di ng to the ma nu fac tu rer’s recom men da tio ns, 
but wi th the fol lowi ng mo di fi  ca tio ns: 1) the in cu-
ba tion ti me for pro teo lysis was 5 min; 2) RNA was 
elu ted from the co lu mn wi th 55 μL RNa se-free wa-
ter and the col lec ted elua te used for a se co nd elu-
tion of RNA from the sa me co lu mn. Stan da rd met-
ho ds (A260/A280 on a Na noD rop or Agi le nt RNA 
6000 Na no kit) are inap prop ria te for as ses sme nt of 
RNA yie ld and qua li ty in the col lec ted elua te be-
cau se RNA car rier that is used in the pro ce ss of 
plas ma RNA iso la tion yiel ds the sig nal, whi ch is too 
do mi na nt re la ti ve to the sig nal of RNA spe cies of 
in te re st. As a con sequen ce, RNA amoun ts ba sed 
on star ti ng vo lu me rat her than RNA quan ti ty is 
used in all ana lyti cal pro ce du res. Elu ted mR NA was 
tran scri bed to cDNA wi th Su per Scri pt VILO cDNA 
Synthe sis Kit (In vit ro gen, Car lsbad, CA, USA). Fir st, 
RNA elua te was in cu ba ted in a wa ter ba th (65 ˚C) 
for 5 min, then im me dia te ly pla ced on ice for anot-
her 5 min. The ma nu fac tu rer’s pro to col was fol-
lowed from then on.
The fol lowi ng TaqMan Ge ne Expres sion As says 
(Ap plied Bio syste ms, Fos ter Ci ty, CA, USA) we re 
used for cDNA quan ti fi  ca tion: Hs00234489_m1 for 
DAP K1 (exon boun da ry 3-4, am pli con len gth 105), 
Hs00234140_m1 for CCL2 (exon boun da ry 1-2, am-
pli con len gth 101) and En do ge nous Con trol 
4326316E for cyclop hi lin A (PPIA). cDNA was ampli-
fi ed by PCR ac cor di ng to the ma nu fac tu rer’s pro-
to col (Roc he Diag nos ti cs, GmbH, Man nheim, Ger-
ma ny), usi ng a 1.5 μL (DAP K1 and PPIA) or 3.75 μL 
(CCL2) of the cDNA so lu tion and the kit com po-
nen ts in a reac tion vo lu me of 25 μL. Al thou gh the 
as say ki ts for cDNA quan ti fi  ca tion are dec la red to 
be mR NA spe ci fi c, in our te st con di tio ns DNA was 
fou nd to in ter fe re in bo th as says. All reac tio ns we-
re run in trip li ca te and the ave ra ge thres ho ld cycle 
of trip li ca tes (Ct) cal cu la ted. Be twee n-run im pre ci-
sion for the who le ana lyti cal pro ce du re (from iso-
la tion to quan ti fi  ca tion), expres sed as coeffi   cie nt 
of va ria tion of Ct, was le ss than 2%. To exclu de the 
pos si bi li ty of exter nal nuc leic aci ds con ta mi na tion 
ne ga ti ve con trol (bla nk) was ana lysed in ea ch PCR 
run. For cli ni cal eva lua tion, the amou nt of ea ch in-
ves ti ga ted tran scri pt was stan dar di zed to the 
amou nt of a re fe ren ce ge ne. PPIA was cho sen as 
the mo st ap prop ria te re fe ren ce ge ne amo ng 11 
can di da tes avai lab le on TaqMan Hu man En do ge-
nous Con trol Pla te (Ap plied Bio syste ms), ba sed on 
the smal le st geo met ric Ct of in di vi dual can di da tes 
and re sul ts from ge No rm, as in de tail des cri bed 
pre vious ly (9).
Sta tis ti cal ana lyses
Da ta are pre sen ted as coun ts; age is pre sen ted as 
me dian and ran ge. Sta tis ti cal ly sig ni fi  ca nt diff e ren-
ce be tween pa tien ts and con tro ls for quan ti ta ti ve 
va riab les (age and plas ma le ve ls of nuc leic aci ds) 
was tes ted usi ng non pa ra met ric Ma nn-Whit ney 
te st.
P va lues < 0.05 we re con si de red sta tis ti cal ly sig ni fi -
ca nt.
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Sta tis ti cal ana lyses we re per for med usi ng SPSS 
17.0 sta tis ti cal sof twa re pac ka ge (SPSS, Inc., Chi ca-
go, IL, USA).
Re sul ts
The cli ni cal cha rac te ris ti cs of the par ti ci pan ts are 
sum ma ri zed in Tab le 1. Heal thy sub jec ts we re 
youn ger (me dian 55 vs. 61 yea rs; P = 0.029). Age 
did not cor re la te wi th any ob ser ved pa ra me ter 
wit hin eit her pa tie nt or con trol group (da ta not 
shown).
Al thou gh the as say ki ts for cDNA quan ti fi  ca tion 
are dec la red to be mR NA spe ci fi c, in our te st con-
di tio ns DNA was fou nd to in ter fe re in DAP K1 and 
CCL2 as say, as con fi r med by: 1) ana lysis of the si ze 
of the am pli fi ed PCR pro duc ts on aga ro se gel elec-
trop ho re sis; 2) run ni ng a PCR reac tion wi th hu man 
DNA; and 3) run ni ng a PCR reac tion wi th sub jec ts’ 
sam ples but omit ti ng the re ver se tran scrip tion (da-
ta not shown). The DNA in ter fe ren ce was con fi r-
med af ter fi  nis hi ng all the expe ri men ts. In te res tin-
gly, the new lot num ber of rea gen ts pur cha sed af-
ter in for mi ng the pro du cer about the un cer tain ty, 
no lon ger showed DNA in ter fe ren ce (da ta not 
shown). Be cau se we used all cDNA sam ples, it was 
not pos sib le to re peat the mea su re men ts wi th the 
new lot num ber of rea gen ts. On the ot her ha nd, it 
was not pos sib le to stu dy in de tail the re la ti ve con-
tri bu tion of DNA and cDNA to the sig na ls ob tai ned 
wi th the old lot num ber of rea gen ts, be cau se we 
used all of them.
The la bo ra to ry fi n din gs are sum ma ri zed in Fi gu re 
1. DAP K1 and CCL2 plas ma le ve ls of nuc leic aci ds 
(mR NA and DNA) we re suc ces sful ly de ter mi ned in 
all pa tien ts and in 31 (out of 33) con tro ls. Pa tien ts 
had, on ave ra ge, 5.1-times hig her plas ma le ve ls of 
DAP K1 nuc leic aci ds than con tro ls (me dian and in-
te rquar ti le ran ge 33.82 (11.40-77.44) vs. 6.63 (2.87-
11.47); P < 0.001). Pa tien ts wi th dia be tes had 5.5-ti-
mes hig her le ve ls than pa tien ts wit hout wit hout 
dia be tes (68.23 (34.12-99.18) vs. 12.38 (7.09-35.48); 
P = 0.006), and the lat ter sti ll had 86.7 % hig her le-
ve ls than the con tro ls (12.38 (7.09-35.48) vs. 6.63 
(2.87-11.47); P = 0.014). On a con tra ry, plas ma le ve ls 
of CCL2 nuc leic aci ds ten ded to be lower in pa tien-
Pa ra me ter Stab le an gi na pa tien ts
Heal thy 
sub jec ts
Gen der (ma les; N/total) 16/29 21/33
Age (yea rs) 61 (46-83)* 55 (38-81)*
Fa mi ly his to ry of CAD (N/total) 7/29 0/33
Smo ki ng sta tus (cur re nt or 
for mer; N/total) 8/29 0/33
Dia be tes (N/total) 12/29 0/33
Co ro na ry ar te riog rap hy 





Sta tin the ra py (N/total) 24/29 0/33
As pi rin the ra py (N/total) 25/29 0/33
ACE in hi bi tor the ra py (N/total) 17/29 0/33
* me dian (mi n-max); CAD - co ro na ry ar te ry di sea se.
TAB LE 1. Cli ni cal cha rac te ris ti cs of sub jec ts.
ts than in con tro ls (12.55 (6.77-38.61) vs. 36.25 (5.90-
74.54); P = 0.062) and, when on ly sta ti n-trea ted pa-
tien ts we re com pa red to the con tro ls, the dec rea-
se reac hed the sig ni fi  can ce (-66.3%; 12.21 (6.41-
26.60) vs. 36.25 (5.90-74.54); P = 0.041). It is no-
tewor thy that 22 sta ti n-trea ted pa tien ts (out of 24) 
we re re cei vi ng as pi rin and 16 pa tien ts ACE in hi bi-
to rs.
Le ve ls of nuc leic aci ds in pa tien ts’ plas ma did not 
cor re la te wi th the num ber of di sea sed co ro na ry 
ar te ries or wi th any ot her ob ser ved pa ra me ter. In 
the con tro ls, plas ma le ve ls of nuc leic aci ds cor re la-
ted neit her wi th plas ma li pi ds nor wi th any ot her 
ob ser ved pa ra me ter. Im por tan tly, plas ma le ve ls of 
nuc leic aci ds did not cor re la te wi th leu ko cyte or 
pla te let coun ts.
Dis cus sion
Our stu dy shows the exis ten ce of ce ll-free nuc leic 
aci ds from DAP K1 and CCL2, i.e. from ge nes res pon-
sib le for at he ros cle ro tic plaque de ve lop me nt and 
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des ta bi li za tion, in plas ma of pa tien ts wi th co ro na-
ry at he ros cle ro sis. Plas ma nuc leic aci ds ana lysis is 
an emer gi ng fi e ld for no n-in va si ve in vi vo as ses-
sme nt and mo ni to ri ng of pat ho lo gic pro ces ses in 
tis sues of their ori gin. It rep re sen ts an al ter na ti ve 
or a sup ple me nt to pro tein ana lysis. Nowa days, 
quan ti ta ti ve and qua li ta ti ve ana lysis of ce ll-free 
nuc leic aci ds is con si de red to be cli ni cal ly use ful in 
no n-in va si ve pre na tal diag no sis, and in diag no sis 
and mo ni to ri ng of nu me rous can ce rs (5), but no vel 
ap pli ca tio ns are emer gi ng al so in ot her cri ti cal ca-
re set tin gs, su ch as acu te co ro na ry syndro me 
(6–8,11). The se nuc leic aci ds can be mea su red pre-
ci se ly in on ly 200 µL of plas ma of pa tien ts wi th 
stab le an gi na as we ll as of heal thy sub jec ts (8,11). 
We be lie ve that wi th the use of hig her plas ma vo-
lu mes for nuc leic aci ds iso la tion (com mer cial ki ts 
are avai lab le) and wi th fur ther im pro ve me nt of 
spe ci fi  ci ty of as says for PCR quan ti fi  ca tion the re 
wi ll be pos sib le to re liab ly mea su re plas ma mR NA 
from DAP K1 and CCL2, thus off e ri ng a new tec-
hnique for no n-in va si ve in vi vo as ses sme nt and 
mo ni to ri ng of ge ne expres sion pro fi  le in vas cu lar 
be ds.
Al thou gh con clu sio ns are not as expec ted and 
DNA in ter fe ren ce in tro du ces un cer tain ty to the 
da ta, the re sul ts of our stu dy are in te res ti ng and 
expli cab le in the lig ht of cur re nt knowled ge. Hi gh 
plas ma le ve ls of DAP K1 nuc leic aci ds in pa tien ts wi-
th stab le an gi na are con sis te nt wi th the cur re nt 
evi den ce that apop to sis is a pro mi ne nt fea tu re of 
at he ros cle ro tic plaque, es pe cial ly in re gio ns wi th a 
hi gh den si ty of mac rop ha ges (1,12). Apop to sis is an 
im por ta nt sour ce of nuc leic aci ds (mR NA and DNA) 
in plas ma (5). Fur ther mo re, DAP K1 is a we ll known 
po si ti ve me dia tor of apop to sis in a wi de ar ray of 
apop to tic syste ms (13) and DAB K1 was fou nd to be 
hig hly expres sed in ca ro tid at he ros cle ro tic plaqu-
es (2). Fi nal ly, pro lon ged hyper glycae mia and/or 
im pai red in su lin sig nal li ng we re al so shown to in-
du ce apop to sis (14). In this res pe ct it shou ld be no-
ted that our stu dy de si gn does not exclu de ot her 
sour ces of DAP K1 nuc leic aci ds. DAP K1 nuc leic aci-
ds con tai ni ng apop to tic bo dies in no n-vas cu lar tis-
sues may es ca pe the eli mi na tion by re ti cu loen dot-
he lial system in tho se tis sues and thus prot ru de in-
to the blood. This cou ld be an ad di tio nal rea son 
for extre me ly hi gh plas ma DAP K1 nuc leic aci ds le-
ve ls in our pa tien ts wi th dia be tes. Unexpec ted ly, 
stab le an gi na pa tien ts had lower plas ma le ve ls of 
CCL2 nuc leic aci ds than con tro ls. He re it is no-
tewor thy that if DNA had had a ma jor con tri bu tion 
to the sig na ls ob tai ned, it wou ld ha ve been diffi   cu-
lt to explain the di ver ge nt re sul ts for plas ma nuc-
leic aci ds le ve ls from CCL2 and DAP K1. Lower plas-
ma nuc leic aci ds le ve ls from CCL2 in pa tien ts wi th 
FI GU RE 1. Plas ma DAP K1 and CCL2 nuc leic aci ds le ve ls in pa tien ts wi th stab le an gi na (N = 29) and in heal thy sub jec ts (N = 33). Plas ma 
le ve ls we re stan dar di zed to the amou nt of re fe ren ce ge ne (PPIA mR NA). Box plo ts de mon stra te in te rquar ti le ran ge (25th and 75th 
per cen ti les), and li ne in si de the box de no tes the me dian bar. The whis ke rs de mon stra te the lar ge st and the smal le st va lues in si de the 
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stab le an gi na cou ld be explai ned as a con sequen-
ce of sta tin pleiot ro py (15). Twen ty-four pa tien ts 
(out of the 29) we re re cei vi ng sta tin the ra py. Sta tin- 
trea ted pa tien ts had lower plas ma con cen tra tio ns 
of CCL2 than tho se wit hout sta tin the ra py (16), and 
sta tin treat me nt sig ni fi  can tly di mi nis hed neoin ti-
mal and me dial CCL2 in a rab bit mo del of at he ros-
cle ro sis (17). Fi nal ly, sta tin treat me nt re du ced CCL2 
mR NA le ve ls in pe rip he ral blood mo no cytes in vi-
vo (18).
To con clu de, ce ll-free nuc leic aci ds from ge nes res-
pon sib le for at he ros cle ro tic plaque de ve lop me nt 
and des ta bi li za tion are pos sib le to quan ti fy in plas-
ma of pa tien ts wi th stab le an gi na and of heal thy 
sub jec ts and the es ti ma ted le ve ls are expli cab le in 
ter ms of cur re nt knowled ge. Fur ther stu dies wi th 
spe ci fi c as says for PCR quan ti fi  ca tion are rea so-
nab le.
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Po vi še na ra zi na DAP K1 te sni že na ra zi na CCL2 nuk lein skih ki se li na u plaz mi 
kod bo les ni ka sa sta bil nom an gi nom pekto ris
Sažetak
Uvod: Pos ta vi li smo hi po te zu da bo les ni ci obo lje li od sta bil ne an gi ne pekto ris ima ju po vi še nu ra zi nu mR NA ge na od go vor nih za stva ra nje i des ta-
bi li za ci ju ate ros kle rot skog pla ka, od nos no iz pro tein ske ki na ze po ve za ne sa smr ću sta ni ce (en gl. dea th-as so cia ted pro tein ki na se, DAP K1) i mo no-
cit nog ke mo tak tskog pro tei na-1 (en gl. mo no cyte che mo tac tic pro tei n-1, CCL2) u plaz mi.
Ma te ri ja li i me to de: Iz plaz me bo les ni ka obo lje lih od sta bil ne an gi ne pekto ris te zdra vih is pi ta ni ka izo li ra li smo nuk lein ske ki se li ne. Uči nje na 
je tran skrip ci ja mo le ku la mR NA u cDNA, te su kvan ti fi  ci ra ne lan ča nom reak ci jom po li me ra zom u stvar nom vre me nu (en gl. rea l-ti me PCR) i stan-
dar di zi ra ne na ko li či nu re fe ren tnog ge na. Rea gen si za kvan ti fi  ka ci ju me to dom PCR dek la ri ra ni su kao spe ci fi č ni za mR NA, no u na šim uv je ti ma 
is pi ti va nja us ta no vi li smo da DNA in ter fe ri ra u oba tes ta.
Re zul ta ti: Ra zi na DAP K1 nuk lein skih ki se li na (mR NA i DNA) u plaz mi bi la je 5,1 pu ta vi ša kod bo les ni ka ne go kod kon trol nih is pi ta ni ka (P < 
0,001), a naj vi še su ra zi ne bi le po ve za ne sa šeće rnom bo les ti. Razi na CCL2 u plaz mi ni je bi la sta tis tič ki zna čaj no ni ža kod sku pi ne bo les ni ka ne go 
kod kon trol nih is pi ta ni ka, dok je kod bo les ni ka li je če nih sta ti ni ma sni že nje ra zi ne pos ta lo sta tis tič ki zna čaj no (- 66,3%; P = 0,041).
Zak lju čak: Dobi ve ne se vri jed nos ti mo gu ob jas ni ti tre nut nim spoz na ja ma. Pot reb na su dalj nja is tra ži va nja spe ci fi č nim tes to vi ma za kvan ti fi  ka-
ci ju mR NA me to dom PCR ka ko bi se mog lo pro ci je ni ti pru ža li taj pris tup nein va ziv no in vi vo od re đi va nje i mo ni to ri ng ra zi ne ek spre si je ge na u 
ate ros kle rot skim le zi ja ma.
Ključ ne ri je či: CCL2; DAP K1; slo bod ne nuk lein ske ki se li ne; plaz ma; sta bil na an gi na pekto ris
